MVision AI receives TGA approval and market authorization for Australia

May 02, 2024 06:10 PM AEST | By EIN Presswire
 MVision AI receives TGA approval and market authorization for Australia
Image source: EIN Presswire
HELSINKI, FINLAND, May 2, 2024 /EINPresswire.com/ -- An application for MVision AI Segmentation (Contour+) has been submitted and accepted by the Therapeutic Goods Administration (TGA) under the “Image Segmentation Application Software” for image analysis algorithms to be used in radiation therapy treatment planning workflows.

Contour+ accelerates the contouring process, provides guidance toward standardization, enhances consistency, and saves time, as confirmed by independent evaluations [1-3] and customer experiences [4]. We have designed Contour+ to steer the clinic's contouring practice towards consensus and compliance with guidelines.

According to the AIHW report, in 2023 it is estimated that around 165,000 cases of cancer will be diagnosed in Australia. This represents an 88% increase in just over 20 years. The annual number of cancer cases diagnosed is expected to surpass 200,000 by 2033. This underscores the importance of radiation therapy departments being prepared to deliver personalized and prompt cancer treatment [5].

MVision AI’s comprehensive GBS™ solution enhances Radiation Oncology professionals' expertise in AI contouring together with a robust Return On Investment (ROI) strategy, allowing you to invest in what truly matters for you. The solution contains 3 innovative products - Contour+, Guide and Verify.

“MVision AI and alphaXRT are thrilled to announce our achievement of this milestone. The implementation of our GBS solution will reduce the inherent time burden on Australian oncology departments when undertaking contouring activities. Combined with our training and validation tools, our GBS solution will ensure that clinical teams remain current with contouring best practices, resulting in a standardized approach when delivering their service for their patients; all of which enables a seamless integration of AI contouring into your department. With our TGA and MDSAP, we are entering the Australian market, which is very important and promising for us!", says Dharanipathy Rangaraj, CEO of MVision.

“As Mvision’s distributor for Australia & New Zealand we are delighted that MVision have been granted TGA approval. Since first meeting MVision in 2022 we have been eager to bring their outstanding Guideline-based (GBS) AI contouring technology to our region. Mvision’s GBS technology really is a win-win solution: it is a significant time saver for radiation oncology professionals, and at the same time improves and standardizes contouring practice in the department.” says Nigel Attwood, CEO of alphaXRT.
For more information on Contour+ and our comprehensive GBS™ solution, please visit MVision.ai or contact us at [email protected].

References:
[1] MVision.ai - MVision AI Contour+ (Guideline-Based AI Segmentation): highlights from an independent validation study using a comprehensive and curated data set
[2] MVision.ai - Research Results of MVision AI Contour+ Models’ Clinical Evaluation
[3] MVision.ai - The voice of customer experience: Dr. Giuseppe Sasso, New Zealand
[4] Australian Institute of health and Welfare - Overview of cancer in Australia, 2023

Sakthy Edamaruku
MVision AI
[email protected]
Visit us on social media:
Facebook
Twitter
LinkedIn
YouTube


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.